Dogwood Therapeutics (DWTX) furnishes shareholder letter with corporate update

Rhea-AI Filing Summary

Dogwood Therapeutics, Inc. submitted a current report noting that it has posted a shareholder letter to its website, dated January 20, 2026. The letter provides a corporate update for shareholders and is included as Exhibit 99.1 to the report. The company specifies that this shareholder letter is being furnished for information purposes under securities regulations and is not being treated as filed or incorporated into other securities law filings.

0001818844false00018188442026-01-202026-01-20

​

​

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

​

FORM 8-K

​

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

​

Date of Report (Date of earliest event reported):  January 20, 2026

​

DOGWOOD THERAPEUTICS, INC.

(Exact Name of Registrant as Specified in Charter)

​

​	​	​
Delaware	001-39811	85-4314201
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

​

​ ​	​
44 Milton Avenue Alpharetta, GA	30009
(Address of principal executive offices)	(Zip Code)

​

Registrant’s telephone number, including area code:  (866) 620-8655

​

(Former name or former address, if changed since last report): N/A

​

Securities registered pursuant to Section 12(b) of the Act:

​

​	​	​
Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value $0.0001	DWTX	Nasdaq Capital Market

​

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

​

​	​
☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
​	​
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
​	​
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
​	​
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

​

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company       ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.       ☐

​

​

​

​

Item 7.01 Regulation FD Disclosure.

On January 20, 2026, the Company posted a shareholder letter to its website providing a corporate update. A copy of the shareholder letter is furnished as Exhibit 99.1.

The information in Item 7.01 of this Current Report on Form 8-K, including the information in the shareholder letter attached as Exhibit 99.1 to this Current Report on Form 8-K is furnished pursuant to Item 7.01 of Form 8-K and shall not be deemed “filed” for the purposes of Section 18 of the Exchange Act or otherwise subject to the liabilities of that section. Furthermore, the information in Item 7.01 of this Current Report on Form 8-K, shall not be deemed to be incorporated by reference in the filings of the Company under the Securities Act.

​

​

Item 9.01 Financial Statements and Exhibits.

​

(d)Exhibits.

​

​	​	​
Exhibit Number	​ ​ ​	Description
99.1	​	Shareholder letter, dated January 20, 2026 (furnished herewith).
104	​	Cover Page Interactive Data File (formatted in Inline XBRL and contained in Exhibit 101)

​

​

​

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

​	​	​
	DOGWOOD THERAPEUTICS, INC.
	By:	/s/ Angela Walsh
	Name:	Angela Walsh
​	Title:	Chief Financial Officer, Corporate Secretary and Treasurer
January 20, 2026	​	​

​

​

​

3

FAQ

What did Dogwood Therapeutics (DWTX) disclose in this 8-K?

Dogwood Therapeutics, Inc. disclosed that it posted a shareholder letter on its website providing a corporate update, and furnished the letter as Exhibit 99.1 to the report.

What is contained in Exhibit 99.1 for Dogwood Therapeutics (DWTX)?

Exhibit 99.1 is a shareholder letter from Dogwood Therapeutics, Inc., dated January 20, 2026, which provides a corporate update and is furnished with the report.

Is the Dogwood Therapeutics (DWTX) shareholder letter considered filed with the SEC?

No. The company states that the information in Item 7.01, including the shareholder letter in Exhibit 99.1, is furnished and shall not be deemed filed or subject to Section 18 of the Exchange Act.

Where can shareholders access Dogwood Therapeutics’ January 20, 2026 corporate update?

Shareholders can access the corporate update through the shareholder letter posted on the company’s website, which is also furnished as Exhibit 99.1 to the current report.

Who signed the Dogwood Therapeutics (DWTX) current report?

The report was signed on behalf of Dogwood Therapeutics, Inc. by Angela Walsh, who serves as Chief Financial Officer, Corporate Secretary and Treasurer.

Does this Dogwood Therapeutics (DWTX) report include financial statements?

The report lists Item 9.01 for financial statements and exhibits but only identifies Exhibit 99.1, the shareholder letter, and Exhibit 104, the cover page interactive data file.